# Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection

> **NCT01924949** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 5 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** LDV/SOF

## Key facts

- **NCT ID:** NCT01924949
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-05
- **Final completion:** 2014-08
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2018-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01924949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01924949, "Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01924949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*